Urinary Osteocalcin Is a Useful Marker for Monitoring the Effect of Alendronate Therapy

Ivaska, Kaisa K.; Pettersson, Kim; Nenonen, Arja; Uusi‐Rasi, Kirsti; Heinonen, Ari; Kannus, Pekka; Väänänen, H. Kalervo

doi:10.1373/clinchem.2005.055541

Cited by 15 publications

(6 citation statements)

References 28 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, correlations between changes in serum osteocalcin level and serum calcium, phosphorous, and ALP were not significant. [24], and Ivaska et al [25]. Consistent with the current study, Aonuma et al [17] stated no significant correlation between BMD and changes in serum osteocalcin levels after treatment with alendronate.…”

Section: Results _________________________________supporting

confidence: 89%

Serum osteocalcin levels in postmenopausal osteoporotic women receiving alendronate

2018

View full text Add to dashboard Cite

Osteoporosis is characterized by low bone mass, changes in the microscopic structure of bone, and increased bone fragility. Monitoring response to treatment is critical for the appropriate management of osteoporosis. Serum osteocalcin has become known as a bone formation biomarker for the evaluation of treatment response in postmenopausal osteoporosis. The present study assessed the effect of alendronate on serum osteocalcin levels in patients with postmenopausal osteoporosis. Thirty-four women with postmenopausal osteoporosis diagnosed by DEXA received alendronate 10 mg/day for 3 months. Serum osteocalcin, calcium, phosphorus, and alkaline phosphatase (ALP) were measured at baseline and after 45 and 90 days. Mean age and duration of menopause were 57.91±7.68 and 9.37±8.43 years, respectively. Mean serum osteocalcin at baseline was 15.27±3.7 ng/ml, which decreased significantly after 45 and 90 days of treatment with alendronate (p=0.009 and p<0.001, respectively). The levels of serum osteocalcin at days 45 and 90 in patients aged < 60 and ≥ 60 years were not significantly different. The levels of serum osteocalcin at days 45 and 90 in patients with a menopause duration of < 5 and ≥ 5 years were not significantly different. No significant difference was observed in serum osteocalcin levels at days 45 and 90 in patients with osteoporosis only in the femoral neck (n=7), only in the lumbar spine (n=20), and in both femoral neck and lumbar spine (n=7). Measurement of serum osteocalcin is a less expensive, more available tool for monitoring the results of treatment in osteoporotic patients. It provides a practical suggestion about the effectiveness of treatment earlier than densitometry. As expected, osteocalcin levels decreased after treatment of osteoporosis.

show abstract

Section: Results _________________________________supporting

confidence: 89%

Serum osteocalcin levels in postmenopausal osteoporotic women receiving alendronate

2018

View full text Add to dashboard Cite

show abstract

“…This is in agreement with earlier findings suggesting that urinary OC may be more related to resorption than formation. (26,34–36)…”

Section: Discussionmentioning

confidence: 99%

Effect of Fracture on Bone Turnover Markers: A Longitudinal Study Comparing Marker Levels Before and After Injury in 113 Elderly Women

Ivaska

Gerdhem

Åkesson

et al. 2007

Journal of Bone and Mineral Research

Self Cite

151

View full text Add to dashboard Cite

In this longitudinal, prospective, and population-based study (n = 1044), seven BTMs were assessed before and after trauma in 113 elderly women (85 with fractures). Markers were not altered in the immediate postfracture period but were clearly elevated during fracture repair. Recent fracture should thus be taken into account when markers are used in clinical practice.Introduction: Fracture may influence the levels of bone turnover markers (BTM) and have implications for their use in clinical practice. In this longitudinal, prospective, and population-based study, we assessed prefracture levels of BTMs and compared them with postfracture levels of the same individuals immediately after fracture and during fracture repair. This is the first study in which the effect of fracture on bone markers has been evaluated with prefracture samples available. Materials and Methods: Serum and urine were collected at the emergency unit from 85 women (77.9 ± 1.8 yr) who sustained a fracture after low-energy trauma and 28 controls (77.8 ± 2.0 yr) with similar trauma but no fracture. All were participants of the Malmö OPRA study (n ‫ס‬ 1044), and pretrauma samples were collected 1.05 ± 0.85 yr before. Results: BTMs sampled within a few hours after fracture were not altered from preinjury levels. Both bone formation and bone resorption markers were, however, significantly increased 4 mo after fracture. The elevation was most pronounced after hip fracture. Bone turnover remained elevated up to 12 mo after fracture. Conclusions: We believe this study extends our knowledge on the skeletal postfracture metabolic processes. In addition, it may provide a basis for future means to monitor pharmacological intervention promoting fracture healing.

show abstract

“…6 In women receiving antiresorptive therapy, Short term changes in bone turnover markers are related to long term changes in BMD and may also predict long term increases therein Serum Osteocalcin can be Considered as a specific marker of osteoblast Function as its levels have been shown to correlate with bone formation rates the change in serum osteocalcin have been shown to correlate with changes in BMD. [7][8][9] The Present study was designed to evaluate significance of serum osteocalcin in evaluation of osteoporosis, relationship between Serum Osteocalcin and BMD (Bone mineral Density) in postmenopausal females with osteoporosis.…”

Section: Introductionmentioning

confidence: 99%

Osteocalcin, a promising marker of osteoporosis: evaluation in post-menopausal females with osteoporosis

Alam

Rana

Alam³

2019

Int J Adv Med

View full text Add to dashboard Cite

Background: Osteocalcin, has high affinity for calcium. In osteoporotic women, deficiency of calcium may lead to lowering of the formation of hydroxyapatite crystals. Thus, in the state of hypo mineralization, free osteocalcin available in the circulation. Therefore, present study was designed to evaluate significance of serum osteocalcin in diagnosis of osteoporosis, and relationship between Serum Osteocalcin and BMD (Bone mineral Density) in postmenopausal females with osteoporosis and without osteoporosis. Methods: One hundred and forty seven post-menopausal women between age 45 to 80 years attending the hospital OPD were studied. To be eligible for the study they had to have been postmenopausal for at least one year. The diagnosis of osteoporosis was made based on T-Scores (BMD) at the lumber spine (L1 to L4 and femaral neck) by DEXA (GE lunar Densitometer). Serum osteocalcin level was estimated by LIAISON osteocalcin assay. Patients with chronic conditions affecting skeletal health and patients on drugs affecting the skeleton were excluded from the study. Results: Serum osteocalcin level in post-menopausal female without osteoporosis was 9.87±1.04ng/ml, while postmenopausal female with osteoporosis had 22.62±2.25ng/ml suggesting significant increase in bone marker level in osteoporotic females (p<0.05.) Correlation study between BMD and osteocalcin showed strong Negative Correlation (r=-0.77, p<0.05). Conclusions: Serum osteocalcin can be considered as a specific marker of osteoblast function as its levels have been shown to correlate with bone formation rates. Thus, serum osteocalcin can be used for diagnosis and monitoring of response to therapy and this may be the better predictor than BMD.

show abstract

Urinary Osteocalcin Is a Useful Marker for Monitoring the Effect of Alendronate Therapy

Cited by 15 publications

References 28 publications

Serum osteocalcin levels in postmenopausal osteoporotic women receiving alendronate

Serum osteocalcin levels in postmenopausal osteoporotic women receiving alendronate

Effect of Fracture on Bone Turnover Markers: A Longitudinal Study Comparing Marker Levels Before and After Injury in 113 Elderly Women

Osteocalcin, a promising marker of osteoporosis: evaluation in post-menopausal females with osteoporosis

Contact Info

Product

Resources

About